Disitamabvedotin, also known as Adissib, is a drug used to treat metastatic gastric cancer. It kills cancer cells by binding to the HER2 receptor on the surface of the cancer cells and releasing the Wieck toxin.
indication
Suitable for patients with HER2 overexpression in locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least 2 rounds of systemic chemotherapy.
effectiveness
On June 9, 2021, ADC's new drug "Vedicizumab for Injection" (code: RC48, trade name: Adissil) was officially approved by the National Medical Products Administration with conditions. The drug is an innovative antibody coupled drug (ADC) independently developed in China, suitable for the treatment of HER2 overexpressing locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) patients who have received at least two types of systemic chemotherapy.
RC48 is the first antibody conjugated (ADC) drug to enter clinical research in China. ADC drugs are novel biopharmaceuticals composed of monoclonal antibodies, linkers, and toxins, capable of delivering precise strikes against tumor cells. RC48 adopts a new humanized antibody with stronger affinity and better endocytosis effect, and uses advanced linkers and small molecule toxin drugs to achieve efficient killing of tumors.
On July 2, 2021, Ediximab was officially launched for sale in China, suitable for the treatment of HER2 overexpressing locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) patients who have received at least two types of systemic chemotherapy.
adverse reaction
Hematological abnormalities (decreased white blood cell count, decreased neutrophil count), elevated transaminases (aspartate aminotransferase, alanine aminotransferase). Common clinical symptoms and signs of adverse reactions include hair loss, fatigue, and decreased sensation.
